Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on the development of drug products that are intended to improve the survival and quality of life for patients who have an unmet medical need. The company's lead product, PCS499 is an or... Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on the development of drug products that are intended to improve the survival and quality of life for patients who have an unmet medical need. The company's lead product, PCS499 is an oral tablet that is an analog of an active metabolite of an already approved drug. It focuses on fibrotic related diseases such as focal segmental glomerulosclerosis, idiopathic pulmonary fibrosis. Its pipeline products comprise PCS6422, PCS12852, and PCS100. Mehr anzeigen
First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri’s ability to deliver more SN-38 to tumors compared...
Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabineResults from this Phase 2 trial will evaluate NGC-Cap’s safety-efficacy profile and help to...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.169 | -20.1430274136 | 0.839 | 0.839 | 0.67 | 70795 | 0.74237381 | CS |
| 4 | -0.2295 | -25.5141745414 | 0.8995 | 1.08 | 0.67 | 66593 | 0.86127119 | CS |
| 12 | -0.5 | -42.735042735 | 1.17 | 1.5 | 0.67 | 372004 | 1.26673636 | CS |
| 26 | -1.06 | -61.2716763006 | 1.73 | 3.1 | 0.67 | 680392 | 1.98060414 | CS |
| 52 | -1.63 | -70.8695652174 | 2.3 | 5.9099 | 0.67 | 1083924 | 3.04028264 | CS |
| 156 | -76.13 | -99.1276041667 | 76.8 | 90.4 | 0.67 | 693988 | 6.71107885 | CS |
| 260 | -75.33 | -99.1184210526 | 76 | 284.798 | 0.67 | 502415 | 12.23295379 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
